



Michael Benatar

Kontakt

Michael Benatar

Publikationen (6)

Koch J, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, Depla E, Weydt P, Meyer T, Grosskreutz J, Soriani M, Attarian S, Weishaupt J, Weyen U, Kuttler J, Zurek G, Rogers M, Feneberg E, Deschauer M, Neuwirth C, Wu J, Ludolph A, Schmidt J, Remane Y, Camu W, Friede T, Benatar M, Weber M, Lingor P, ROCK-ALS Study group. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2024; 23:1133-1146.

Benatar M, Hansen T, Rom D, Geist M, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg L, Juntas-Morales R, Chio A, Andersen P, Pradat P, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal N, Meyer T, Hanna M, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph A, Neuwirth C, Nations S, Shefner J, Turner M, Wu J, Bennett R, Dang H, Sundgreen C, ORARIALS-01 trial team. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Neurol* 2024; 23:687-699.

Lingor P, Tostmann R, Neuwirth C, Meyer T, Lengenfeld T, Leha A, Kuttler J, Kollwe K, Kassubek J, Ilse B, Günther R, Ahmed R, Langbein T, Wu J, Hennecke C, Hussain S, Statland J, Koch J, Benatar M. Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. *Amyotroph Lateral Scler Frontotemporal Degener* 2021; 22:419-425.

Lingor P, Koch J, Ludolph A, Frontini R, Blankenstein C, Bidner H, Kuzma-Kozakiewicz M, Benatar M, Günther R, Neuwirth C, Leha A, Hilgers R, Friede T, Camu W, Weber M, ROCK-ALS Investigators. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. *Front Neurol* 2019; 10:293.

van den Berg L, McDermott C, Piro E, Rosenfeld J, Silani V, Turner M, Weber M, Brooks B, Miller R, Mitsumoto H, Lomen-Hoerth C, Gubitza A, Genge A, Sorenson E, Gronseth G, Macklin E, Andrews J, Baloh R, Benatar M, Berry J, Chio A, Corcia P, Airlie House ALS Clinical Trials Guidelines Group. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. *Neurology* 2019; 92:e1610-e1623.

Nordin A, Burkhardt C, Neuwirth C, Holmøy T, Morita M, Tysnes O, Benatar M, Wu J, Lange D, Bisgård C, Asgari N, Tarvainen I, Brännström T, Weber M, Schweikert K, Grehl T, Akimoto C, Wuolikainen A, Alstermark H, Forsberg K, Baumann P, Pinto S, de Carvalho M, Hübers A, Nordin F, Ludolph A, Weishaupt J, Meyer T, Andersen P. Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. *Amyotroph Lateral Scler Frontotemporal Degener* 2016; 18:256-264.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch